These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

257 related articles for article (PubMed ID: 26483357)

  • 1. Safety of oral dronabinol during opioid withdrawal in humans.
    Jicha CJ; Lofwall MR; Nuzzo PA; Babalonis S; Elayi SC; Walsh SL
    Drug Alcohol Depend; 2015 Dec; 157():179-83. PubMed ID: 26483357
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Opioid withdrawal suppression efficacy of oral dronabinol in opioid dependent humans.
    Lofwall MR; Babalonis S; Nuzzo PA; Elayi SC; Walsh SL
    Drug Alcohol Depend; 2016 Jul; 164():143-150. PubMed ID: 27234658
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intranasal buprenorphine alone and in combination with naloxone: Abuse liability and reinforcing efficacy in physically dependent opioid abusers.
    Walsh SL; Nuzzo PA; Babalonis S; Casselton V; Lofwall MR
    Drug Alcohol Depend; 2016 May; 162():190-8. PubMed ID: 27012435
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effects of dronabinol during detoxification and the initiation of treatment with extended release naltrexone.
    Bisaga A; Sullivan MA; Glass A; Mishlen K; Pavlicova M; Haney M; Raby WN; Levin FR; Carpenter KM; Mariani JJ; Nunes EV
    Drug Alcohol Depend; 2015 Sep; 154():38-45. PubMed ID: 26187456
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cannabinoid modulation of opioid analgesia and subjective drug effects in healthy humans.
    Babalonis S; Lofwall MR; Sloan PA; Nuzzo PA; Fanucchi LC; Walsh SL
    Psychopharmacology (Berl); 2019 Nov; 236(11):3341-3352. PubMed ID: 31201479
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nabiximols as an agonist replacement therapy during cannabis withdrawal: a randomized clinical trial.
    Allsop DJ; Copeland J; Lintzeris N; Dunlop AJ; Montebello M; Sadler C; Rivas GR; Holland RM; Muhleisen P; Norberg MM; Booth J; McGregor IS
    JAMA Psychiatry; 2014 Mar; 71(3):281-91. PubMed ID: 24430917
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effect of high-dose dronabinol (oral THC) maintenance on cannabis self-administration.
    Schlienz NJ; Lee DC; Stitzer ML; Vandrey R
    Drug Alcohol Depend; 2018 Jun; 187():254-260. PubMed ID: 29689485
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Modest opioid withdrawal suppression efficacy of oral tramadol in humans.
    Lofwall MR; Walsh SL; Bigelow GE; Strain EC
    Psychopharmacology (Berl); 2007 Oct; 194(3):381-93. PubMed ID: 17605004
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of the NK1 antagonist, aprepitant, on response to oral and intranasal oxycodone in prescription opioid abusers.
    Walsh SL; Heilig M; Nuzzo PA; Henderson P; Lofwall MR
    Addict Biol; 2013 Mar; 18(2):332-43. PubMed ID: 22260216
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dronabinol and lofexidine for cannabis use disorder: A randomized, double-blind, placebo-controlled trial.
    Levin FR; Mariani JJ; Pavlicova M; Brooks D; Glass A; Mahony A; Nunes EV; Bisaga A; Dakwar E; Carpenter KM; Sullivan MA; Choi JC
    Drug Alcohol Depend; 2016 Feb; 159():53-60. PubMed ID: 26711160
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A phase III, randomized, multi-center, double blind, placebo controlled study of safety and efficacy of lofexidine for relief of symptoms in individuals undergoing inpatient opioid withdrawal.
    Gorodetzky CW; Walsh SL; Martin PR; Saxon AJ; Gullo KL; Biswas K
    Drug Alcohol Depend; 2017 Jul; 176():79-88. PubMed ID: 28527421
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of tradipitant, a selective NK1 antagonist, on response to oxycodone in humans.
    Coe MA; Lofwall MR; Vessels V; Nuzzo PA; Walsh SL
    Psychopharmacology (Berl); 2021 Jul; 238(7):1857-1866. PubMed ID: 33988725
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Subjective, cognitive and cardiovascular dose-effect profile of nabilone and dronabinol in marijuana smokers.
    Bedi G; Cooper ZD; Haney M
    Addict Biol; 2013 Sep; 18(5):872-81. PubMed ID: 22260337
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Within-subject comparison of the psychopharmacological profiles of oral hydrocodone and oxycodone combination products in non-drug-abusing volunteers.
    Zacny JP; Gutierrez S
    Drug Alcohol Depend; 2009 Apr; 101(1-2):107-14. PubMed ID: 19118954
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of extended-release tramadol for treatment of prescription opioid withdrawal: a two-phase randomized controlled trial.
    Lofwall MR; Babalonis S; Nuzzo PA; Siegel A; Campbell C; Walsh SL
    Drug Alcohol Depend; 2013 Nov; 133(1):188-97. PubMed ID: 23755929
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Guanfacine Attenuates Adverse Effects of Dronabinol (THC) on Working Memory in Adolescent-Onset Heavy Cannabis Users: A Pilot Study.
    Mathai DS; Holst M; Rodgman C; Haile CN; Keller J; Hussain MZ; Kosten TR; Newton TF; Verrico CD
    J Neuropsychiatry Clin Neurosci; 2018; 30(1):66-76. PubMed ID: 28641496
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dronabinol for the treatment of cannabis dependence: a randomized, double-blind, placebo-controlled trial.
    Levin FR; Mariani JJ; Brooks DJ; Pavlicova M; Cheng W; Nunes EV
    Drug Alcohol Depend; 2011 Jul; 116(1-3):142-50. PubMed ID: 21310551
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High-dose methadone produces superior opioid blockade and comparable withdrawal suppression to lower doses in opioid-dependent humans.
    Donny EC; Walsh SL; Bigelow GE; Eissenberg T; Stitzer ML
    Psychopharmacology (Berl); 2002 May; 161(2):202-12. PubMed ID: 11981600
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects associated with double-blind omission of buprenorphine/naloxone over a 98-h period.
    Correia CJ; Walsh SL; Bigelow GE; Strain EC
    Psychopharmacology (Berl); 2006 Dec; 189(3):297-306. PubMed ID: 17013637
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Human Abuse Potential of Oral NKTR-181 in Recreational Opioid Users: A Randomized, Double-Blind, Crossover Study.
    Ge X; Henningfield JE; Siddhanti S; Jobes J; Lu L; Xie S; Ziola M; Kelsh D; Vince B; Di Fonzo CJ; Tagliaferri M; Zalevsky J; Doberstein SK; Hoch U; Eldon MA
    Pain Med; 2020 Feb; 21(2):e114-e126. PubMed ID: 31553457
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.